Odgerel CO, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851–8.

Article  PubMed  Google Scholar 

Australian Institute of Health and Welfare. Mesothelioma in Australia 2021. Canberra: AIHW; 2023.

Google Scholar 

Nicholson AG, et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol. 2020;15(1):29–49.

Article  CAS  PubMed  Google Scholar 

•• Baas P, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86. Seminal paper establishing PD1 and CTLA4 blockade as an effective first-line therapy in pleural mesotheoioma patients.

Article  CAS  PubMed  Google Scholar 

Maria Carmela P, et al. IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. J Clin Oncol. 2023;41(17_suppl):LBA8505–LBA8505.

Article  Google Scholar 

Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17(4):260–71.

CAS  PubMed  PubMed Central  Google Scholar 

Sincock A, Seabright M. Induction of chromosome changes in Chinese hamster cells by exposure to asbestos fibres. Nature. 1975;257(5521):56–8.

Article  CAS  PubMed  Google Scholar 

Gibas Z, et al. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet. 1986;20(3–4):191–201.

Article  CAS  PubMed  Google Scholar 

Cheng JQ, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54(21):5547–51.

CAS  PubMed  Google Scholar 

Sekido Y, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–31.

CAS  PubMed  Google Scholar 

Bianchi AB, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A. 1995;92(24):10854–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bott M, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scherpereel A, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https://doi.org/10.1183/13993003.00953-2019.

Article  CAS  PubMed  Google Scholar 

World Health Organization. Thoracic Tumours, 5th Edition. Lyon: International Agency for Research on Cancer. 2021. https://doi.org/10.4345/138807.

Ivanov SV, et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer. 2009;124(3):589–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Creaney J, et al. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med. 2022;14(1):58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

López-Ríos F, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Can Res. 2006;66(6):2970–9.

Article  Google Scholar 

Louw A, et al. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know. Curr Opin Pulm Med. 2019;25(4):354–61.

Article  CAS  PubMed  Google Scholar 

Testa JR, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

OMIM. Tumor predisposition syndrome 1 (TPDS1). #614327. 2022 [updated 4 August 2022; cited 16 December 2022]. Available from: https://www.omim.org/entry/614327.

Baumann F, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.

Article  CAS  PubMed  Google Scholar 

Pastorino S, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):JCO2018790352.

Article  PubMed  Google Scholar 

Belcaid L, et al. New pathogenic germline variants identified in mesothelioma. Lung Cancer. 2023;179:107172.

Article  CAS  PubMed  Google Scholar 

Mitchell OD, et al. Germline variants incidentally detected via tumor-only genomic profiling of patients with mesothelioma. JAMA Netw Open. 2023;6(8):e2327351–e2327351.

Article  PubMed  PubMed Central  Google Scholar 

Bueno R, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16.

Article  CAS  PubMed  Google Scholar 

Hmeljak J, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quetel L, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14(6):1207–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nair NU, et al. Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma. Cell Rep Med. 2023;4(2):100938.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zauderer MG, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Lancet Digit Health. 2021;3(9):e565–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Dagogo-Jack I, et al. Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape. JCO Precis Oncol. 2022;6:e2100422. Manuscript identifies frequently mutated genes in a large mesothelioma cohort.

Article  PubMed  Google Scholar 

Dermawan JK, et al. EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: report of 3 cases in support of an emerging entity. Genes Chromosomes Cancer. 2022;61(10):592–602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desmeules P, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol. 2017;41(7):980–8.

Article  PubMed  PubMed Central  Google Scholar 

Hung YP, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 2018;4(2):235–8.

Article  PubMed  Google Scholar 

Michal M, et al. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features. Genes Chromosomes Cancer. 2023;62(5):267–74.

Article  CAS  PubMed  Google Scholar 

Nash A, Firth Nee Phan T, Creaney J. New markers for management of mesothelioma. Semin Respir Crit Care Med. 2023;44(4):491–501.

Article  PubMed  Google Scholar 

Louw A, et al. BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol. 2022;17(7):921–30.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2022 [cited 2022 19 December; Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companiondiagnostic-devices-in-vitro-and-imaging-tools].

Hiltbrunner S, et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127(11):1997–2005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alay A, et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer. 2021;9(2):e001601. https://doi.org/10.1136/jitc-2020-001601.

Mannarino L, et al. Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study. Int J Mol Sci. 2022;23(10):5786. https://doi.org/10.3390/ijms23105786.

• Zhang M, et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun. 2021;12(1):1751. Demonstrates tumour evolution, showing NF2 activation is predominately a late event.

Article  CAS  PubMed  PubMed Central  Google Scholar